ArticleBMC infectious diseases2025
The relationship between the alveolar epithelial lining fluid concentration of intravenous plus inhaled polymyxin B and clinical efficacy in patients with pneumonia caused by carbapenem-resistant gram-negative bacilli: a prospective cohort study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Physiologically Based Pharmacokinetic Modeling of Inhaled Polymyxin B: From Rabbit Optimization to Human Predictions.Pharmaceutical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundNebulization combined with intravenous polymyxin B (PMB) for carbapenem-resistant gram-negative bacilli (CRGNB) pneumonia still has a number of failures that may be related to insufficient alveolar epithelial lining fluid (ELF) concentration of PMB. This study aimed at determining the relationship between the alveolar ELF concentration of PMB and clinical efficacy after intravenous (IV) plus inhaled (IH) PMB.
methodsSeventy-five patients with pneumonia caused by CRGNB were treated with IH plus IV PMB. Alveolar lavage fluid was collected before and after nebulization, and ELF was calculated according to the urea dilution equation. Differences in clinical outcomes between patients with high and low peak and trough concentrations of ELF concentration of PMB were compared separately according to the ROC curve grouping strategy. The primary outcome was favorable clinical outcome. The secondary outcomes included microbiological outcome and time to bacterial eradication, time to renormalize body temperature, CRGNB-related and all-cause mortality, 28-day survival, length of hospitalization, inflammation marker levels and side effects related to PMB.
resultsClinical efficacy and bacterial clearance were higher in the high ELF peak concentration group than in the low one (total efficacy: 94.44% vs. 48.72%, total bacterial clearance: 63.89% vs. 38.46%, both P < 0.05). The clinical effective rate was higher in the high ELF trough concentration group than in the low one (88.89% vs. 43.33%, P < 0.05). The 28-day survival rate was higher in the high ELF peak and trough concentration group than in the low one (peak: 86.11% vs. 38.46%, trough: 75.56% vs. 40.00%, both P < 0.05).
conclusionsPatients with high PMB alveolar ELF concentrations demonstrated more favorable clinical outcomes than those with low concentrations.
trial registrationThis trial was registered. The Chinese trial registration number is ChiCTR2100044087. The date of registration is 9-3-2021. The registered name is that clinical study on intravenous drip and aerosol inhalation of polymyxin B for the treatment of pneumonia due to multidrug-resistant gram-negative bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.